[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Lin TL, Shih LY, Hung YS, Kuo TT: Thymic hyperplasia following successful chemotherapy for Hodgkin's lymphoma: report of a case. Chang Gung Med J; 2009 Jan-Feb;32(1):98-103
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for thymic hyperplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymic hyperplasia following successful chemotherapy for Hodgkin's lymphoma: report of a case.
  • A recurrent mediastinal mass in a patient following treatment for Hodgkin's lymphoma presents a diagnostic challenge.
  • We report a 17-year-old boy with nodular sclerosing Hodgkin's lymphoma, stage IIIsA, who achieved complete response after 6-cycle chemotherapy with doxorubicin, bleomycin, vinblastine and dacarbazine and developed thymic hyperplasia 6 months later.
  • Most patients were young, had the nodular sclerosis subtype of Hodgkin's lymphoma, were in an advanced stage, and had a latency of 2 to 12 months following successful chemotherapy.
  • Resection of the tumor for tissue diagnosis is mandatory to establish an accurate diagnosis and thus avoid further harmful therapy.
  • [MeSH-major] Hodgkin Disease / drug therapy. Thymus Gland / pathology

  • Genetic Alliance. consumer health - Thymic hyperplasia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19292945.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China (Republic : 1949- )
  • [Number-of-references] 19
  •  go-up   go-down


2. Wu SJ, Chen CY, Su IJ, Tang JL, Chou WC, Ko BS, Huang SY, Yao M, Tsay W, Chen YC, Wang CH, Tien HF: Clinical characteristics and treatment response of Hodgkin's lymphoma in Taiwan. J Formos Med Assoc; 2008 Jan;107(1):4-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and treatment response of Hodgkin's lymphoma in Taiwan.
  • BACKGROUND/PURPOSE: Hodgkin's lymphoma (HL) is particularly rare in Asia, including Taiwan.
  • The report concerning its clinical features and treatment outcomes in Asians is limited.
  • The nodular sclerosis type (NS-HL) was the most common histopathologic subtype (45%), followed by mixed cellularity (29%), lymphocyte predominant (13%), and lymphocyte depleted subtype (2%).
  • Induction therapy led to complete remission (CR) in 87% of patients.
  • CONCLUSION: The treatment response of HL in Taiwan is good and comparable to that in Western countries.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18218572.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


3. Jones GL, Taylor PR, Windebank KP, Hoye NA, Lucraft H, Wood K, Angus B, Proctor SJ: Outcome of a risk-related therapeutic strategy used prospectively in a population-based study of Hodgkin's lymphoma in adolescents. Br J Cancer; 2007 Jul 2;97(1):29-36
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of a risk-related therapeutic strategy used prospectively in a population-based study of Hodgkin's lymphoma in adolescents.
  • The aim was to assess outcome in a population-based cohort of adolescents with Hodgkin's lymphoma (HL) diagnosed in the UK's northern region over a 10-year period.
  • Seven had nodular lymphocyte-predominant HL, 48 classical HL (cHL).
  • Application of the Scottish and Newcastle Lymphoma Group (SNLG) prognostic index meant 21 patients were considered high risk (index >or=0.5).
  • They received PVACEBOP multi-agent chemotherapy as primary therapy.
  • Standard risk patients (SNLG index <0.5) were treated with standard ChlVPP or ABVD chemotherapy+/-radiotherapy.
  • Scottish and Newcastle Lymphoma Group indexing is not valid for patients under 16.
  • Seven patients relapsed but all entered complete remission after salvage therapy.
  • The data suggest that older adolescents with high-risk HL require intensive protocols as primary therapy to secure optimal outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Bleomycin / therapeutic use. Cohort Studies. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Male. Survival Analysis. Treatment Outcome. Vinblastine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2769-79 [9256118.001]
  • [Cites] Eur J Cancer. 1991;27(5):624-9 [1828974.001]
  • [Cites] QJM. 1998 Feb;91(2):131-9 [9578895.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(13):2058-63 [10070311.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4541-50 [15542805.001]
  • [Cites] Pediatr Blood Cancer. 2005 Oct 15;45(5):670-5 [16007600.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7604-13 [16186595.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2520-6 [16735704.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3736-44 [10577845.001]
  • [Cites] Histopathology. 2000 Jan;36(1):69-86 [10632755.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1500-7 [10735898.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):397-403 [10917558.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1591-8 [1714950.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):100-8 [8418221.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2160-6 [7523608.001]
  • [Cites] Eur J Cancer. 1994;30A(7):1045-6 [7946575.001]
  • [Cites] Am J Pathol. 1995 Apr;146(4):812-8 [7717448.001]
  • [Cites] Bone Marrow Transplant. 1995 Dec;16(6):777-82 [8750269.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2622-30 [9215833.001]
  • [Cites] Cancer Causes Control. 2001 Nov;12(9):803-12 [11714108.001]
  • [Cites] Eur J Cancer. 2002 Apr;38(6):795-806 [11937314.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3081-7 [12118021.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3088-94 [12118022.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3765-71 [12228196.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):2026-33 [12743158.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1579-85 [15370209.001]
  • [Cites] Cancer Treat Rep. 1982 Apr;66(4):949-59 [7042093.001]
  • [Cites] Cancer. 1985 Dec 1;56(11):2547-56 [4052932.001]
  • [Cites] J Clin Oncol. 1987 May;5(5):742-9 [3572464.001]
  • [Cites] J Clin Oncol. 1988 Dec;6(12):1845-50 [3058876.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):897-906 [9508171.001]
  • (PMID = 17533403.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  • [Other-IDs] NLM/ PMC2359673
  •  go-up   go-down


Advertisement
4. Biasoli I, Stamatoullas A, Meignin V, Delmer A, Reman O, Morschhauser F, Coiffier B, Bosly A, Diviné M, Brice P: Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer; 2010 Feb 1;116(3):631-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group.
  • BACKGROUND: Nodular, lymphocyte-predominant Hodgkin lymphoma (NLPHL) represents a rare entity.
  • To determine the histologic transformation (HT) rate to diffuse large B-cell lymphoma (DLBCL) and long-term outcomes, 164 patients were selected after histologic review.
  • The median patient age was 30 years (range, 6-69 years), 80% of patients were men, 83% had Ann Arbor stage I/II disease, 65% had supradiaphragmatic-disease; 27% received radiotherapy, 9% received chemotherapy, 29% received combined-modality therapy, and 35% were followed with a watch-and-wait strategy.
  • All 106 treated patients achieved complete remission and 66 patients developed disease recurrence at a median of 3.3 years (range, 0.4-18.3 years after diagnosis).
  • The majority of recurrences were NLPHL, but 19 patients progressed to DLBCL at a median of 4.7 years (range, 0.4-18 years after diagnosis).
  • The 19 patients who had HT were treated with curative intent: Nine patients received high-dose therapy with subsequent autologous stem cell transplantation (ASCT), and 10 patients received different chemotherapy regimens.
  • CONCLUSIONS: This long-term follow-up study confirmed that NLPHL is a separate entity that has a favorable clinical presentation and outcome despite frequent recurrences.
  • The current findings also emphasize the importance of biopsies at the time patients develop recurrent disease to evaluate HT.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Transformation, Neoplastic. Child. Female. Humans. Longitudinal Studies. Lymphoma / classification. Lymphoma / pathology. Male. Middle Aged. Recurrence. Time Factors

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 American Cancer Society.
  • (PMID = 20029973.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


5. Pijuan L, Vicioso L, Bellosillo B, Ferrer MD, Baró T, Pedro C, Lloreta-Trull J, Munné A, Serrano S: CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection. Am J Surg Pathol; 2005 Oct;29(10):1399-403
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.
  • It has shown efficacy in patients with B-cell non-Hodgkin lymphoma and also in CD20-positive Hodgkin lymphoma.
  • Recently, CD20-negative tumors have been described after Rituximab therapy.
  • We report a 34-year-old man with a history of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), treated with different chemotherapy regimens, including anthracyclines and Rituximab.
  • After 4 years in complete remission, he developed a CD20-negative T-cell-rich B-cell lymphoma (TCRBCL) presenting as multiple lung lesions.
  • This case shows the difficulties in the diagnosis of CD20-negative lymphomas when the number of tumor cells is low and when they are found in a predominant T-cell context.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / metabolism. Antineoplastic Agents / therapeutic use. Hodgkin Disease / drug therapy. Lung Neoplasms / pathology. Lymphoma, B-Cell / pathology. Neoplasms, Second Primary / pathology. T-Lymphocytes / immunology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160485.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


6. Ozer N, Deveci OS, Kaya EB, Demircin M: Mediastinal lymphoma causing extrinsic pulmonary stenosis. Turk Kardiyol Dern Ars; 2009 Sep;37(6):421-4
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal lymphoma causing extrinsic pulmonary stenosis.
  • A 20-year-old female was referred to our center with a cystic mass detected by transthoracic echocardiography and thoracic computed tomography, in the superoanterior mediastinum, 5.5 x 5.5 x 7 cm in size, causing main pulmonary trunk compression.
  • The pathological diagnosis of the mass was stage IIa nodular sclerosing Hodgkin's lymphoma.
  • The patient received postoperative chemotherapy and thoracal radiotherapy.
  • [MeSH-major] Lymphoma / complications. Mediastinal Neoplasms / complications. Pulmonary Valve Stenosis / etiology
  • [MeSH-minor] Echocardiography, Transesophageal. Female. Humans. Pulmonary Artery / surgery. Pulmonary Artery / ultrasonography. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20019459.001).
  • [ISSN] 1016-5169
  • [Journal-full-title] Türk Kardiyoloji Derneği arşivi : Türk Kardiyoloji Derneğinin yayın organıdır
  • [ISO-abbreviation] Turk Kardiyol Dern Ars
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


7. van Grotel M, Lam KH, de Man R, Beishuizen A, Pieters R, van den Heuvel-Eibrink MM: High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only. Leuk Lymphoma; 2006 Aug;47(8):1504-10
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.
  • Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare variant of Hodgkin's lymphoma (HL) in children.
  • Since specific immunohistochemical staining has become available, NLPHL can be separated from classical Hodgkin's lymphoma (cHL) more accurately.
  • Scarce information is available about pediatric NLPHL treated with chemotherapy only.
  • Therefore, clinical characteristics, treatment, response and outcome of seven pediatric NLPHL patients, median age 9.2 years (range 7.5 - 14.2 years), diagnosed between 1986 - 2003 among 58 HL patients, uniformly treated in a single center with chemotherapy only, were evaluated.
  • The median follow-up time was 4.2 years (range 2.1 - 10.2 years).
  • NLPHL patients were stage I (n = 5), II (n = 2), whereas cHL, median age 11.4 years (range 3.3 - 15.9 years), were stage I (n = 8), II (n = 17), III (n = 9), IV (n = 1).
  • Upfront treatment of NLPHL patients consisted of six courses of epirubicin, bleomycin, vinblastine and dacarbazine (EBVD) without radiotherapy, whereas cHL patients received six courses of EBVD (n = 14) or 4 - 6 courses of EBVD/MOPP (mitoxin, oncovin, procarbazine, prednison; n = 21).
  • Chemotherapy was used as primary treatment thereby aiming to avoid radiotherapy with potential serious side effects to growing jaws and thyroid.
  • These three were salvaged with second-line chemotherapy without radiation therapy (RT) and are in second CR.
  • This study shows that apart from histology, immunohistochemistry (ICH) is required for diagnosing NLPHL.
  • Moreover, it illustrates that although cure of pediatric NLPHL is feasible with chemotherapy only, high dosages of cytotoxic drugs are necessary as salvage treatment in a relatively high proportion of patients after relapse.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Bleomycin / administration & dosage. Child. Dacarbazine / administration & dosage. Epirubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Recurrence. Remission Induction / methods. Retrospective Studies. Salvage Therapy / methods. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Aug;47(8):1450-1 [16966251.001]
  • (PMID = 16966260.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


8. Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rüdiger T, Borchmann P, Schnell R, Diehl V, Engert A, Reiser M: Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood; 2008 Jan 1;111(1):109-11
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).
  • Because nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) express CD20, rituximab may be used as a nonmutagenic treatment option to avoid late toxicities in this rather indolent entity.
  • Between 1999 and 2004, the German Hodgkin Study Group (GHSG) investigated the activity of rituximab (375 mg/m(2) in 4 doses) in a phase 2 trial in 21 relapsed or refractory NLPHL patients.
  • The initial diagnosis of NLPHL was confirmed in 15 of the 21 enrolled patients by reference pathology.
  • The remaining cases were reclassified as Hodgkin lymphoma transformed to T-cell rich B-cell lymphoma (TCRBCL; n = 2) or CD20(+) classical Hodgkin lymphoma (cHL; n = 4).
  • In NLPHL patients the overall response rate was 94%, including 8 complete remission (CR) and 6 partial remission (PR).
  • With a median follow-up of 63 months (range, 3-84), the median time to progression was 33 months, with the median overall survival (OS) not reached.
  • Thus, rituximab is highly effective in relapsed and refractory NLPHL.
  • This study is registered at http://www.klinisches-studienzentrum.de/trial/285.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Female. Germany. Humans. Kaplan-Meier Estimate. Lymphocytes / pathology. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / pathology. Male. Middle Aged. Recurrence. Remission Induction. Rituximab. T-Lymphocytes / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17938252.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


9. Galán L, Sánchez AC, Cantos B, Provencio M: Rituximab monotherapy in relapsed lymphocyte-predominant Hodgkin's lymphoma. Clin Transl Oncol; 2010 May;12(5):384-6
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab monotherapy in relapsed lymphocyte-predominant Hodgkin's lymphoma.
  • Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) accounts for approximately 5% of Hodgkin's lymphoma, presents with early-stage disease and has an indolent course.
  • Treatment is not well established.
  • We present a patient diagnosed with NLPHL and treated with Rituximab second-line therapy after chemotherapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Lymphocyte Activation / drug effects. Recurrence. Rituximab

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2009;76(1):26-9 [19033694.001]
  • [Cites] Blood. 2008 Jan 1;111(1):109-11 [17938252.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4285-9 [12586628.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):106-10 [16007877.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4261-7 [12377971.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:266-72 [17124071.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2675-81 [15231567.001]
  • [Cites] Curr Opin Oncol. 2009 Sep;21(5):397-400 [19606035.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3295-301 [16873669.001]
  • [Cites] Blood. 2003 Jan 15;101(2):420-4 [12509381.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):776-83 [10071266.001]
  • (PMID = 20466624.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


10. Illés A, Simon Z, Tóth E, Rosta A, Miltényi Z, Molnár Z: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres. Pathol Oncol Res; 2008 Dec;14(4):411-21
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres.
  • Clinicopathological features of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) differ from those of the classical Hodgkin lymphoma (cHL).
  • Our aim was to examine clinical presentation, therapeutic and survival results of NLPHL patients in Hungary based on the data of two centres, and incidentally we analyzed the clinicopathological characteristics and differential diagnostic difficulties of this rare entity.
  • We analyzed the clinical features, treatment and survival data of 536 Hodgkin lymphoma patients who had been diagnosed and primarily treated in our institutes between 1995 and 2004.
  • Mean follow-up time was 82.7 (3-144) months of the total 536 HL patients.
  • Sixteen (3%) of the patients were diagnosed with NLPHL, 93% of them presented with early-stage disease.
  • One patient received chemotherapy alone, six received only involved field radiotherapy while six underwent combined modality treatment.
  • Two NLPHL cases transformed to non-Hodgkin's lymphoma.
  • In NLPHL group there were no late or multiple relapses and none of them died.
  • CONCLUSIONS: NLPHL is a rare disease, thus these are limited experiences with its diagnosis and treatment.
  • Since the disease has an excellent outcome, it is very important to prefer less toxic or local therapies to reach long term survival similar to that of the normal population.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / mortality. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Hungary. Immunohistochemistry. Lymphoma / pathology. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1995 Sep 15;86(6):2312-20 [7662978.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1731-8 [11920535.001]
  • [Cites] Cancer. 2005 Sep 15;104(6):1221-9 [16094666.001]
  • [Cites] Am J Surg Pathol. 1988 Aug;12(8):599-606 [3041849.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:77-82 [2049323.001]
  • [Cites] Hematol Oncol. 2006 Sep;24(3):146-50 [16729353.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] Blood. 2008 Jan 1;111(1):109-11 [17938252.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3753-8 [12881319.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):903-11 [12826882.001]
  • [Cites] Semin Radiat Oncol. 2007 Jul;17(3):184-9 [17591565.001]
  • [Cites] Acta Haematol. 1986;76(1):29-32 [3098024.001]
  • [Cites] Orv Hetil. 2002 Mar 31;143(13):651-61 [11975042.001]
  • [Cites] Blood. 1989 Jan;73(1):47-56 [2462943.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4285-9 [12586628.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):106-10 [16007877.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1346-56 [14508396.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1683-7 [16093276.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2002 Sep 24;65(3):195-202 [12242134.001]
  • [Cites] Blood. 1996 Jul 15;88(2):657-66 [8695813.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1551-7 [15370206.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):128-32 [16330953.001]
  • [Cites] Cancer Res. 1966 Jun;26(6):1063-83 [5947336.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Oct;21(5):787-804 [17908620.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:266-72 [17124071.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Ann Oncol. 1998;9 Suppl 5:S45-56 [9926237.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Oct;21(5):897-914 [17908627.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):776-83 [10071266.001]
  • (PMID = 18431694.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


11. Itami J: [Hodgkin lymphoma]. Nihon Igaku Hoshasen Gakkai Zasshi; 2002 Apr;62(5):215-20
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hodgkin lymphoma].
  • In the newly published WHO classification for tumors of the hematopoietic and lymphoid tissues, Hodgkin's disease has been renamed Hodgkin lymphoma, which reflects the recent confirmation of its germinal center B-cell origin.
  • In the classification, nodular lymphocyte-predominant Hodgkin lymphoma has been added as a new entity with an excellent prognosis.
  • Multimodality therapy with chemo- plus radiotherapy can improve disease-free survival, but overall survival remains unchanged.
  • In advanced stages, chemotherapy plays a decisive role, with radiation therapy used as an adjuvant for bulky and/or slowly responding tumors.
  • Long-term follow-up of cured Hodgkin patients has revealed increased incidences of solid malignancies and ischemic heart disease more than 15 years after therapy.
  • Breast cancer and ischemic heart disease appear to be related to mantle irradiation, although sophisticated modern radiation therapy techniques are demonstrated to lower the incidence of these long-term morbidities.
  • Meticulous radiation therapy remains the most effective tool for local control of Hodgkin lymphoma.
  • [MeSH-major] Evidence-Based Medicine. Hodgkin Disease / radiotherapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12043226.001).
  • [ISSN] 0048-0428
  • [Journal-full-title] Nihon Igaku Hōshasen Gakkai zasshi. Nippon acta radiologica
  • [ISO-abbreviation] Nihon Igaku Hoshasen Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 28
  •  go-up   go-down


12. Khoury JD, Jones D, Yared MA, Manning JT Jr, Abruzzo LV, Hagemeister FB, Medeiros LJ: Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma. Am J Surg Pathol; 2004 Apr;28(4):489-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma.
  • The significance of bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma is unknown.
  • Of 275 patients diagnosed as lymphocyte predominant Hodgkin lymphoma at our institution (1983-2003), we identified 7 patients with purely nodular disease in the diagnostic lymph node biopsy specimen who also had bone marrow involvement.
  • The latter was detected at the time of initial diagnosis in four patients, after one cycle of chemotherapy in one patient, and at relapse in two patients.
  • All patients had laboratory, radiologic, and/or morphologic evidence of aggressive disease at the time of detection of bone marrow involvement.
  • At last follow-up, four patients had died of their disease and three were alive following therapy.
  • In conclusion, a small subset of patients in whom lymph node biopsy shows nodular lymphocyte predominant Hodgkin lymphoma with a purely nodular pattern also may have lymphoma in the bone marrow.
  • Although the best terminology for these bone marrow lymphomas is uncertain, the aggressive clinical behavior of these neoplasms supports the need for intensive therapy.
  • [MeSH-major] Bone Marrow Neoplasms / pathology. Hodgkin Disease / pathology. Lymphocytes

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15087668.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Hall GW, Katzilakis N, Pinkerton CR, Nicolin G, Ashley S, McCarthy K, Daw S, Hewitt M, Wallace WH, Shankar A: Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report. Br J Haematol; 2007 Sep;138(6):761-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report.
  • This report describes the clinical outcomes and follow-up records of 42 children with nodular lymphocyte predominant Hodgkin lymphoma (LPHL) treated on United Kingdom Children's Cancer Study Group (UKCCSG) HD1 (1982-1992) and HD2 protocols (1992-2000).
  • In both trials, only patients with stage IA disease had the option of being treated with either involved field radiation alone or combination chemotherapy consisting of chlorambucil, vinblastine, procarbazine and prednisolone (ChlVPP).
  • Patients with all other stages were treated with ChlVPP chemotherapy.
  • Six children relapsed after primary therapy.
  • In conclusion, children with low-stage LPHL treated between 1982 and 2000 according to the UK strategy for classical Hodgkin lymphoma (HL) had an excellent prognosis.
  • There have been no second malignancies or transformations to B-cell non-Hodgkin lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Chlorambucil / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Great Britain. Humans. Ireland. Male. Prednisone / therapeutic use. Procarbazine / therapeutic use. Prospective Studies. Recurrence. Remission Induction. Survival Rate. Vinblastine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760808.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 18D0SL7309 / Chlorambucil; 35S93Y190K / Procarbazine; 5V9KLZ54CY / Vinblastine; VB0R961HZT / Prednisone; CHIVPP protocol
  •  go-up   go-down


14. van Spronsen DJ, Peh SC, Vrints LW, van Imhoff GW, Poppema S: Clinical drug-resistant nodular sclerosing Hodgkin's lymphoma is associated with decreased bcl-2 expression in the surrounding lymphocytes and with increased bcl-2 expression in the Reed-Sternberg cells. Histopathology; 2000 Nov;37(5):420-6
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical drug-resistant nodular sclerosing Hodgkin's lymphoma is associated with decreased bcl-2 expression in the surrounding lymphocytes and with increased bcl-2 expression in the Reed-Sternberg cells.
  • Identification of patients with Hodgkin's lymphoma who are primary refractory to chemotherapy will have great impact on treatment planning.
  • Several studies have indicated that up-regulation of the bcl-2 proto-oncogene expression in non-Hodgkin's lymphoma can cause resistance to chemotherapeutic drugs.
  • For this reason we investigated the relationship between expression of bcl-2, the pro-apoptotic protein Bax and MIB-1 with clinical drug-resistance in Hodgkin's lymphoma.
  • METHODS AND RESULTS: Seven patients with nodular sclerosis Hodgkin's lymphoma under 40 years of age, who failed to achieve complete remission upon primary chemotherapy and 10 matched patients who did achieve complete response were selected from the Eindhoven Cancer Registry.
  • Tissue sections from both groups of patients were stained for bcl-2, Bax and MIB-1.
  • CONCLUSION: A high percentage of Reed-Sternberg cells expressing bcl-2 protein and a low expression of bcl-2 proteifi in the surrounding lymphocytes is associated with treatment-failure, and subsequent poor survival in young patients with nodular sclerosing Hodgkin's lymphoma.
  • [MeSH-major] Hodgkin Disease / metabolism. Lymphocytes / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Reed-Sternberg Cells / metabolism
  • [MeSH-minor] Adolescent. Adult. Antigens, Nuclear. Cell Count. Drug Resistance, Neoplasm. Female. Humans. Immunohistochemistry. Ki-67 Antigen. Male. Neoplasm Staging. Nuclear Proteins / metabolism. Proto-Oncogene Proteins / metabolism. Remission Induction. Sclerosis / pathology. Survival Rate. bcl-2-Associated X Protein

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11119123.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / BAX protein, human; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


15. Maeda LS, Advani RH: The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma. Curr Opin Oncol; 2009 Sep;21(5):397-400
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.
  • PURPOSE OF REVIEW: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare subset of Hodgkin lymphoma that is distinct from classical Hodgkin lymphoma (cHL).
  • Traditionally, NLPHL has been included with cHL in clinical trials with excellent prognosis reported in several series.
  • RECENT FINDINGS: Three series have reported the efficacy of 4 weekly doses of rituximab in all stages of NLPHL, both in the treatment-naive and relapsed settings.
  • Emerging data also suggest that longer courses of antibody therapy may improve the duration of response.
  • SUMMARY: Rituximab appears to offer a nonchemotherapy-based effective treatment option, which is well tolerated.
  • Ongoing studies are required to further define the optimal patient population who may benefit from rituximab and evaluate its role in maintenance as well as in combination with radiotherapy and chemotherapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / immunology. Hodgkin Disease / drug therapy. Lymphocytes / pathology
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Humans. Immunologic Factors / administration & dosage. Immunologic Factors / therapeutic use. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19606035.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 19
  •  go-up   go-down


16. Dunleavy KM, Butrynski J, Steinberg S, Grant N, White T, Jaffe ES, Wilson WH: Phase II study of EPOCH infusional chemotherapy in relapsed or refractory Hodgkin's lymphoma (HL). A report on toxicity, efficacy and prognostic indicators of outcome. J Clin Oncol; 2004 Jul 15;22(14_suppl):6598

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of EPOCH infusional chemotherapy in relapsed or refractory Hodgkin's lymphoma (HL). A report on toxicity, efficacy and prognostic indicators of outcome.
  • : 6598 Background: In relapsed/refractory HL, an effective and well tolerated salvage regimen has important roles both prior to autologous stem cell transplant (SCT) and as palliative therapy in patients (pts) who are ineligible for or have failed SCT.
  • Pts received fixed dose EPOCH chemotherapy (etoposide 200 mg/m<sup>2</sup>, vincristine 1.6 mg/m<sup>2</sup> (no cap) and doxorubicin 40 mg/m<sup>2</sup> CIVI x 96-hrs D1-4; cyclophosphamide 750 mg/m<sup>2</sup> IV D5 and prednisone 60 mg/m<sup>2</sup> qd D1-6 ) with G-CSF q21 days until disease progression or stabilization over ≥ 2 cycles.
  • Histology included nodular sclerosis 34 (64%), mixed cellularity 3 (25%), and lymphocyte depleted 5 (9%) classical HL, and nodular lymphocyte predominant HL 1 (2%).
  • 24 (45%) pts had had ≥ 2 prior regimens, 27 (51%) pts received chemotherapy within the previous 10 mos, and 40 (75%) pts had responded to their last treatment.
  • There was one treatment related death.
  • 45 (84%) pts responded with 23 (44%) CR and 21 (40%) PR.
  • Multivariate analysis revealed that the no. of prior drugs and response to the preceding regimen significantly influenced OS and PFS; in addition PFS was significantly influenced by performance status and mos since previous chemotherapy.
  • It should be considered as salvage therapy prior to SCT or for palliation in incurable HL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016222.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Drakos E, Rassidakis GZ, Leventaki V, Cotta CV, Vega F, Medeiros LJ: Nodular lymphocyte predominant Hodgkin lymphoma with clusters of LP Cells, acute inflammation, and fibrosis: a syncytial variant. Am J Surg Pathol; 2009 Nov;33(11):1725-31
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular lymphocyte predominant Hodgkin lymphoma with clusters of LP Cells, acute inflammation, and fibrosis: a syncytial variant.
  • Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has clinicopathologic, immunophenotypic, and molecular features that are distinct from classical Hodgkin lymphoma (cHL).
  • Distinguishing these entities is usually straightforward, but unusual variants of NLPHL have been described that can be problematic diagnostically and potentially have clinical significance.
  • We describe a case of NLPHL showing a variant histologic pattern characterized by small and large clusters of lymphocyte predominance cells within nodules defined by follicular dendritic cell meshworks, associated with numerous neutrophils and areas of internodular fibrosis.
  • The resulting combination, not previously reported, closely mimicked the syncytial variant of nodular sclerosis cHL.
  • After chemotherapy the patient was free of disease 14 years later.
  • In our review of the literature we identified rare cases of NLPHL that had similar histologic features, but lacked the neutrophilic infiltration.
  • Recognition of this rare variant, facilitated by immunohistochemical studies in this case, further expands the morphologic spectrum of NLPHL.
  • [MeSH-major] Hodgkin Disease / pathology. Lymph Nodes / pathology. Lymphadenitis / pathology. Lymphocytes / pathology. Lymphoma, Follicular / pathology
  • [MeSH-minor] Acute Disease. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Bleomycin / therapeutic use. Dacarbazine / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Fibrosis. Humans. Immunohistochemistry. Male. Neutrophils / pathology. Radiotherapy, Adjuvant. Sclerosis. Vinblastine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19730363.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


18. Niu Y, Shi YK, He XH, Feng FY, Zhou LQ, Gu DZ: [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2008 Aug;30(8):630-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
  • OBJECTIVE: To compare the efficacy of chemotherapy alone, radiotherapy alone and combined-modality therapy in the treatment for early-stage Hodgkin's lymphoma (HL).
  • They were stratified into several groups based on initial treatment strategy: chemotherapy alone (CT group, n = 22), radiotherapy alone (RT group, n = 18), combined-modality therapy (CMT group, n = 109) and surgical resection (SR group, n = 1).
  • Chemotherapy regimens were mainly ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) and MOPP (mechlorethamine, vincristine, procarbazine and prednisone).
  • RESULTS: The pathological types included nodular sclerosis (NS, n = 84), mixed-cellularity (MC, n = 39), lymphocyte-predominant (LP, n = 23), lymphocyte-depleted (LD, n = 3) and nodular lymphocyte predominant Hodgkin's disease (NLPHD, n = 1).
  • There were 33 patients with complete response (CR), 109 with partial response (PR), 5 with stable disease (SD) and 3 with progressive disease (PD) after initial therapy.
  • The overall 7-yr survival rate was 89.3%, and treatment failure rate at 6 years was 18.8%.
  • The response rate of CMT group was superior to that of CT group, and the patients with nodular sclerosis or mixed-cellularity type had significantly lower risk of treatment failure (P = 0.009 and 0.019, respectively).
  • The multivariate analysis revealed that the treatment strategies affected the prognosis significantly.
  • The risk of failure of chemotherapy alone was 2.52 times higher than that of combined-modality therapy (P = 0.004).
  • The patients in CMT group suffered more adverse effects than those in either CT or RT groups, which mainly consisted of leucopenia, alopecia and gastrointestinal symptoms.
  • CONCLUSION: Combined-modality therapy is more effective than chemotherapy alone or radiotherapy alone in the treatment for early stage Hodgkin's lymphoma.
  • Though its acute adverse effects are more severe than that of chemotherapy or radiotherapy alone, it may reduce the risk of treatment failure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Radiotherapy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Alopecia / chemically induced. Bleomycin / adverse effects. Bleomycin / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Dacarbazine / adverse effects. Dacarbazine / therapeutic use. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Leukopenia / chemically induced. Male. Mechlorethamine / adverse effects. Mechlorethamine / therapeutic use. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / adverse effects. Prednisone / therapeutic use. Procarbazine / adverse effects. Procarbazine / therapeutic use. Proportional Hazards Models. Remission Induction. Retrospective Studies. Survival Rate. Vinblastine / adverse effects. Vinblastine / therapeutic use. Vincristine / adverse effects. Vincristine / therapeutic use. Young Adult


19. Culić S, Armanda V, Kuljis D, Kuzmic I, Pranic-Kragic A, Jankovic S: Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl. Pediatr Hematol Oncol; 2006 Dec;23(8):661-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl.
  • Biologic treatments including antibody-based therapies are still in early-phase development in Hodgkin lymphoma.
  • The authors present the case of a 10-year-old girl with massive, solid, unilateral cervical, nodular lymphocyte-predominant Hodgkin lymphoma.
  • Chemotherapy (doxorubicin, bleomycin, vinblastine, and dacarbazine [ABVD]) and radiotherapy were given, according to the Italian Association of Pediatric Hematology and Oncology (AIEOP) MH-96 study protocol, but the patient failed to enter complete remission.
  • Novel therapies, such as rituximab, may be useful for children with CD20+ nodular lymphocyte-predominant Hodgkin lymphoma.
  • To the authors' knowledge, this is the first report of CD20+ nodular lymphocyte-predominant Hodgkin lymphoma treated with rituximab in children.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / immunology. Antigens, Neoplasm / immunology. Hodgkin Disease / drug therapy. Immunologic Factors / therapeutic use
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Child. Combined Modality Therapy. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Remission Induction. Rituximab. Tomography, X-Ray Computed. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17065142.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antigens, Neoplasm; 0 / Immunologic Factors; 11056-06-7 / Bleomycin; 4F4X42SYQ6 / Rituximab; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


20. Harris MA, Radford JA, Deakin DP, James RD, Swindell R, Cowan RA: Limited field radiotherapy for early stage, infra-diaphragmatic Hodgkin's lymphoma. Clin Oncol (R Coll Radiol); 2004 Feb;16(1):53-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited field radiotherapy for early stage, infra-diaphragmatic Hodgkin's lymphoma.
  • AIMS: To analyse the treatment outcome for patients with stage I and II infra-diaphragmatic Hodgkin's lymphoma.
  • Twenty-five out of 33 patients received radiotherapy alone, three out of 33 patients received minimal initial chemotherapy (MIT) (4 weeks VAPEC B) and five patients received six cycles of ChlVPP EVA hybrid chemotherapy before radiotherapy.
  • Histological subtype was lymphocyte predominant (15/33), nodular sclerosis (11/33), mixed cellularity (4/33), lymphocyte-rich classical (1/33) and unclassifiable (2/33).
  • The median time to relapse was 37 months (range 7-65 months).
  • All five relapses had received radiotherapy alone and four were salvaged with chemotherapy.
  • There have been four second malignancies and one patient transformed to high-grade non-Hodgkin's lymphoma.
  • No patient has died of Hodgkin's lymphoma.
  • CONCLUSIONS: In our cohort of patients with infra-diaphragmatic stage I and II Hodgkin's lymphoma treated with limited-field radiotherapy, no patients died from uncontrolled disease.
  • The use of MIT may reduce the risk of relapse and obviate the need for conventional salvage chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / radiotherapy. Neoplasm Staging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Chlorambucil / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Procarbazine / administration & dosage. Retrospective Studies. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14768756.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 18D0SL7309 / Chlorambucil; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; ChlVPP-EVA regimen; VAPEC-B protocol
  •  go-up   go-down


21. Kotila TR, Aken'ova YA, Shokunbi WA, Akingbola TS, Fasola FA: Hodgkin's disease after treatment for Burkitt's lymphoma: case report. East Afr Med J; 2001 Jun;78(6):334-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's disease after treatment for Burkitt's lymphoma: case report.
  • Hodgkin's disease and non-Hodgkin's lymphomas are interrelated disorders which have been reported to occur either simultaneously or sequentially in the same patient.
  • We report here the development of nodular sclerosing type Hodgkin's disease in a patient two decades after successful treatment for Burkitt's lymphoma with cyclophosphomide and abdominal resection (AR).
  • While the onset of symptoms after treatment for Burkitt's lymphoma was seven years definitive diagnosis of Hodgkin's disease was only made 22 years after the initial diagnosis of Burkitt's lymphoma.
  • The recurrent and solitary nature ofthe lymphadenopathy and the fact that it was initially reported as reactive hyperplasia is typical of nodular lymphocyte predominant Hodgkin's disease.
  • We believe that there was a transitory period of the malignancy as nodular lymphocyte predominant Hodgkin's disease.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Burkitt Lymphoma / drug therapy. Cyclophosphamide / adverse effects. Hodgkin Disease / diagnosis. Neoplasms, Second Primary / diagnosis

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12002116.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Kenya
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


22. Unal A, Sari I, Deniz K, Ozkan M, Kontas O, Eser B, Cetin M: Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab. Leuk Lymphoma; 2005 Nov;46(11):1613-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab.
  • Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare tumor type distinct from classical Hodgkin lymphoma and its familial form is unusual.
  • The two cases (mother at age 48 and son at age 30 years) of NLPHL in advanced clinical stage are described.
  • This chemotherapy was well tolerated and the patients reached complete remission.
  • In patients with NLPHL, CHOP-R regimen should be used as an alternative treatment regimen to obtain a good long-lasting response without any adverse events.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / pathology. Lymphocytes / pathology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Family Health. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Prednisolone / therapeutic use. Remission Induction / methods. Rituximab. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236615.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


23. Büyükpamukçu M, Varan A, Akyüz C, Atahan L, Ozyar E, Kale G, Köksal Y, Kutluk T: The treatment of childhood Hodgkin lymphoma: improved survival in a developing country. Acta Oncol; 2009;48(1):44-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of childhood Hodgkin lymphoma: improved survival in a developing country.
  • BACKGROUND: To evaluate the clinical characteristics, treatment regimens, and outcome of children with Hodgkin lymphoma in a developing country over a period of 34 years.
  • METHODS: This paper retrospectively evaluates the treatment and prognosis of 614 children with Hodgkin lymphoma disease between 1971 and 2005.
  • All patients were treated with chemotherapy, and also received radiotherapy.
  • Histopathologic subtypes were mixed cellularity (344 patients), nodular sclerosis (90), lymphocytic predominance (62), lymphocytic depletion (46), unclassified types (69), and nodular lymphocyte predominant Hodgkin lymphoma (3).
  • Overall (OS) and event-free survival (EFS) rates were 83 and 60%, though OS rates varied according to chemotherapy protocol; age; presence of B symptoms, leukocytosis, anemia, and extranodal involvement; and stage at diagnosis.
  • Over the years, the median age of patients increased, as did the frequency of the nodular sclerosing type of disease.
  • The increase in the median age and in the frequency of the nodular-sclerosing type are thought to be related to the development status of Turkey.
  • The ABVD protocol yielded the best survival rates and should be used for treatment of patients with Hodgkin lymphoma.
  • [MeSH-major] Hodgkin Disease / mortality. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Child, Preschool. Female. Humans. Male. Multivariate Analysis. Neoplasm Staging. Survival Rate. Treatment Outcome. Turkey / epidemiology. Young Adult


24. Thakker MM, Perez VL, Moulin A, Cremers SL, Foster CS: Multifocal nodular episcleritis and scleritis with undiagnosed Hodgkin's lymphoma. Ophthalmology; 2003 May;110(5):1057-60
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal nodular episcleritis and scleritis with undiagnosed Hodgkin's lymphoma.
  • PURPOSE: To report the case of a patient with undiagnosed Hodgkin's lymphoma who presented with coexistent unilateral nodular episcleritis and scleritis.
  • The patient was found to have multifocal nodular episcleritis and scleritis that was not responsive to topical steroids or systemic nonsteroidal anti-inflammatory treatment.
  • A cervical lymph node biopsy showed Reed-Sternberg cells and a chronic lymphocytic infiltrate consistent with nodular sclerosing Hodgkin's lymphoma.
  • Systemic chemotherapy was instituted for the Hodgkin's disease; this therapy abolished the nodular scleritis.
  • CONCLUSIONS: This case raises the possibility of concurrent undiagnosed systemic vasculitis with only an ocular manifestation with Hodgkin's lymphoma, either as a coincidence or as a paraneoplastic syndrome.
  • Moreover, it emphasizes the important role of tissue biopsy in establishing diagnosis and directing treatment.
  • [MeSH-major] Eye Neoplasms / diagnosis. Hodgkin Disease / diagnosis. Scleritis / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 by the American Academy of Ophthalmology.
  • (PMID = 12750114.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


25. Nemets A, Ben Dor D, Barry T, Ducach A, Blumental R, Ben Alon D, Lugassy G: Variant Richter's syndrome: a rare case of classical Hodgkin's lymphoma developing in a patient with chronic lymphocytic leukemia treated with fludarabine. Leuk Lymphoma; 2003 Dec;44(12):2151-4
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variant Richter's syndrome: a rare case of classical Hodgkin's lymphoma developing in a patient with chronic lymphocytic leukemia treated with fludarabine.
  • We report a case of a 52-year-old male who developed classical Hodgkin's lymphoma (HL) four years after diagnosis of stage Rai II (Binet B) chronic lymphocytic leukemia (CLL).
  • An inguinal lymph node biopsy revealed both classical Hodgkin's lymphoma, nodular sclerosing type grade 2 and CLL.
  • Treatment with MOPP/ABVD was started and fever subsided within 3 days.
  • Since fludarabine has become standard therapy in CLL such Richter's variant could be the result of therapy, an induced prolonged and severe immunosuppression.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / pathology. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Biopsy. Bone Marrow / pathology. Cyclophosphamide / therapeutic use. Disease Progression. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Syndrome. Time Factors

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14959863.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


26. Moralidis E, Mandala E, Venizelos I, Arsos G, Zafiriadu E, Goutzioulis M, Karakatsanis C: A breast fibroadenoma mimicking an extranodal deposit of Hodgkin's lymphoma in 67Ga imaging. Br J Radiol; 2009 Mar;82(975):e58-62
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A breast fibroadenoma mimicking an extranodal deposit of Hodgkin's lymphoma in 67Ga imaging.
  • We present the case of a young woman with classical nodular sclerosing Hodgkin's lymphoma (clinical stage IIB).
  • A post-treatment (67)Ga scan showed complete remission of the disease with normal tracer uptake in the left breast.
  • However, a few months after treatment, a faint left mammary concentration of (67)Ga was observed.
  • This unusual presentation is a new addition to the literature on false-positive (67)Ga findings and chemotherapy-associated tracer changes.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Contrast Media. Fibroadenoma / radionuclide imaging. Gallium Radioisotopes. Hodgkin Disease / radionuclide imaging
  • [MeSH-minor] Diagnosis, Differential. False Positive Reactions. Female. Humans. Lymphatic Metastasis. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19211906.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Gallium Radioisotopes
  •  go-up   go-down


27. Krugmann J, Sailer-Höck M, Müller T, Gruber J, Allerberger F, Offner FA: Epstein-Barr virus-associated Hodgkin's lymphoma and legionella pneumophila infection complicating treatment of juvenile rheumatoid arthritis with methotrexate and cyclosporine A. Hum Pathol; 2000 Feb;31(2):253-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-associated Hodgkin's lymphoma and legionella pneumophila infection complicating treatment of juvenile rheumatoid arthritis with methotrexate and cyclosporine A.
  • We describe the case of a 53-month-old girl with juvenile rheumatoid arthritis (JRA), complicated by the occurrence of Hodgkin's lymphoma and Legionella pneumophila infection during immunosuppressive treatment with methotrexate (MTX) and cyclosporine A (CSA).
  • The girl had received variable anti-inflammatory combination therapy, including MTX for 28 months and CSA for 3 months.
  • Autopsy showed Epstein-Barr virus (EBV)-associated nodular sclerosing Hodgkin's lymphoma.
  • The present case is the second reported to occur in a child, and it lends support to the hypothesis that immunosuppressive treatment may contribute to an increased risk of the development of EBV-associated lymphoproliferative disorders (LPD) in pediatric patients suffering from JRA.
  • [MeSH-major] Arthritis, Rheumatoid / drug therapy. Epstein-Barr Virus Infections / etiology. Hodgkin Disease / virology. Immunosuppressive Agents / adverse effects. Legionnaires' Disease / etiology


28. Scheinpflug K, Schmitt J, Jentsch-Ullrich K, Roessner A, Franke A: Thymic hyperplasia following successful treatment for nodular-sclerosing Hodgkin's disease. Leuk Lymphoma; 2003 Sep;44(9):1615-7
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymic hyperplasia following successful treatment for nodular-sclerosing Hodgkin's disease.
  • Clinical and histological investigations proved nodular-sclerosing Hodgkin's lymphoma.
  • The patient received combined modality treatment according to the protocols of the German Hodgkin's Disease Study Group and achieved complete remission.
  • Six months later the chest X-ray and thoracic CT-scan showed mediastinal tumor masses suggesting relapsed Hodgkin's disease.
  • Surprisingly, the histological investigation showed thymic hyperplasia as well as the absence of any signs of Hodgkin lymphoma.
  • Thymic hyperplasia is well known as a potential differential diagnosis of mediastinal space-occupying lesions and also as a long-term complication in patients cured of Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / drug therapy. Thymus Gland / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Hyperplasia. Mediastinal Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Remission Induction. Thymectomy

  • Genetic Alliance. consumer health - Thymic hyperplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14565667.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 14
  •  go-up   go-down






Advertisement